Ionis Pharmaceuticals: A Promising Start To Tryngolza & Other Drug Launches To Add To Its Extensive Pipeline! 

Ionis Pharmaceuticals recently reported its first-quarter 2025 financial results. During this period, the company achieved revenue of $132 million, a 10% year-over-year increase, driven largely by the early success of its first independent commercially launched product, TRYNGOLZA, for Familial Chylomicronemia Syndrome (FCS). The TRYNGOLZA launch exceeded expectations with over $6 million in net product sales, marking a significant milestone as Ionis transitions into a commercial-stage biotech company.